Holen Sie sich die Stockscreener-App
11.66
1.93%
-0.23
Handel nachbörslich:
11.66
Climb Bio Inc Aktie (CLYM) Neueste Nachrichten
Raymond James adds Climb Bio stock to favorites list on drug potential - Investing.com Canada
Climb Bio, Inc.(NasdaqGM: CLYM) added to S&P Biotechnology Select Industry Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to S&P Global BMI Index - marketscreener.com
Director Stephen Thomas Sells 100,000 Shares of Climb Bio Inc (CLYM) - GuruFocus
Climb Bio (CLYM) director sells 100K shares in preset plan - Stock Titan
CLYM: CLYM116 and budoprutug advance with best-in-class data, Q12-week dosing, and pivotal trials ahead - TradingView
CLYM: CLYM116 and budoprutug advance with best-in-class profiles and key data readouts expected soon - TradingView
Climb Bio (NASDAQ: CLYM) director files to sell insider stake - Stock Titan
CLYM Stock Price, Quote & Chart - ChartMill
Climb Bio presents initial Phase 1 data for CLYM116 - Traders Union
Climb Bio at Wells Fargo conference: two antibody bets draw focus - Investing.com Nigeria
H.C. Wainwright raises Climb Bio stock price target on drug data By Investing.com - Investing.com Australia
H.C. Wainwright raises Climb Bio stock price target on drug data - Investing.com Australia
Oppenheimer Adjusts Price Target on Climb Bio to $25 From $18, Maintains Outperform Rating - Moomoo
Oppenheimer raises Climb Bio stock price target on IgAN data By Investing.com - Investing.com Canada
Oppenheimer raises Climb Bio stock price target on IgAN data - Investing.com
H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $25 to $40 - Moomoo
symbol__ Stock Quote Price and Forecast - cnn.com
Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Phreesia (PHR) - The Globe and Mail
Baird raises Climb Bio stock price target to $25 on trial data - Investing.com Canada
BTIG raises Climb Bio stock price target to $32 on phase 1 data - Investing.com Australia
Baird raises Climb Bio stock price target to $25 on trial data By Investing.com - Investing.com South Africa
BTIG raises Climb Bio stock price target to $32 on phase 1 data By Investing.com - Investing.com South Africa
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug - Yahoo Finance
Climb Bio Announces Positive Phase 1 Trial Outcomes for CLYM116 Targeting IgA Nephropathy - Kalkine Media
Baird Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $25 - Moomoo
Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule - Benzinga
Climb Bio rises on trial data for kidney drug (CLYM:NASDAQ) - Seeking Alpha
CLYM: CLYM116 shows robust, durable APRIL and IgA suppression with a favorable safety profile in phase I - TradingView
Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data - Yahoo Finance
Why is Climb Bio stock sliding today? By Investing.com - Investing.com Canada
Climb Bio Reports Encouraging Initial Phase 1 CLYM116 Data - TipRanks
Climb Bio stock surges 17% on positive drug trial results - Investing.com
Climb Bio stock surges 17% on positive drug trial results By Investing.com - Investing.com India
Climb Bio reports phase 1 data for IgA nephropathy drug By Investing.com - Investing.com Nigeria
Climb Bio reports phase 1 data for IgA nephropathy drug - investing.com
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating - globenewswire.com
Climb Bio to Present at Upcoming Investor Conferences - markets.businessinsider.com
Climb Bio Stock Up In Pre-Market Ahead Of CLYM116 Data Tomorrow - RTTNews
Climb Bio Inc. (CLYM) Holds Gains: Stock Trades at $13.9 as $14.6 Resistance Caps UpsideLeveraged ETF Flow - dars.gov.et
CLYM Q2 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesPeak Earnings Alert - dars.gov.et
CLYM Q2 2026 Earnings: Narrowed Loss Per Share Beats Estimates, Stock Still Slips 3.25%Earnings Forecast Report - careplusvn.com
Should Climb Bio’s IgA Nephropathy Phase 2 Partnership Shift How CLYM Investors View Its Pipeline Strategy? - Sahm
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):